Navigation Links
3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
Date:10/28/2008

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), disrupt the quality of life for patients, put a tremendous burden on family caregivers, and cost society billions of dollars annually. The most consistent risk factor for developing neurodegenerative disease is aging. Because of the dramatic increase in life expectancy, the incidence of individuals afflicted with the aging-associated disorders is on the rise representing a major health problem. A commonality shared among this diverse set of disorders is the progressive and relentless loss of certain populations of neurons. Current medications for neurodegenerative diseases alleviate only the symptoms associated with these diseases but do not affect the underlying cause degeneration of neurons. Because neuronal loss continues unabated, such palliative treatments have no effect on disease progression. The identification of small-molecule inhibitors of neuronal death is thus of urgent and critical importance.

In the November issue of EBM, researchers at the University of Texas at Dallas and Southern Methodist University have identified a class of compounds, 3-substituted indolones, that can protect neurons from degeneration. Furthermore, the group has conducted a structure-activity relationship study to identify substituent groups that are important for neuroprotective efficacy. A previous study by the same group demonstrated that one of these 3-substituted indolones, called GW5074, prevents neurodegeneration and improves behavioral outcome in a mouse model of neurodegeneration. The senior author, Dr. Santosh D'Mello said "More recent but unpublished work by our group and Doris Kretzschmar, a collaborator at the Oregon Health and Science University, found that GW5074 and other related 3-substituted indolones are also protective in a fly model of Alzheimer's disease. " The current study identifies several compounds that are more efficacious than GW5074 and that display no cytotoxicity even when used at high doses. These 3-substituted indolones are thus novel and promising candidate therapeutic agents for pre-clinical testing against human neurodegenerative conditions. According to Dr. D'Mello, "Studies into the mechanisms underlying neuronal apoptosis has identified several molecules that can be targeted in developing drugs to treat neurodegenerative diseases. Some of these have been tested in human clinical studies but have not proven to be effective at reducing neurodegeneration in patients. Our study has identified some 3-substituted indolones that might be suitable for development as therapeutic agents. The structure-activity relationship analysis we have described in our report, although not exhaustive, also provides useful information on which other efficacious 3-substituted indolones can be synthesized and tested in pre-clinical and clinical studies".

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "The work by D'Mello and colleagues has provided the basis for testing new versions of 3-substituted indolones for efficacy in the treatment of Alzheimer's disease and other neurodegenerative disorders. These drugs provide promising new therapeutic approaches to deal with the underlying cause of these disorders: neuronal cell death."


'/>"/>

Contact: Dr. Santosh R. D'Mello
dmello@utdallas.edu
972-883-2520
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
2. GEN reports on novel tools for deciphering biological networks
3. Novel publishing approach puts textbook in more hands
4. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
5. Childrens National researchers develop novel anti-tumor vaccine
6. LIAI launches new division to look at novel approaches to heart disease and inflammation
7. Conaway Lab identifies novel mechanism for regulation of gene expression
8. Scientists identify novel inhibitor of human microRNA
9. Using novel tool, UD researchers dig through cell trash and find treasure
10. Novel anti-cancer mechanism found in long-lived rodents
11. Novel fungus helps beetles to digest hard wood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that Martine Rothblatt ... Therapeutics will provide an overview and update on the ... Annual Health Care Conference. The presentation will ... a.m. Eastern Time, and can be accessed via a ...
(Date:4/27/2016)... , ... April 27, 2016 , ... Global Stem ... GSCG Advisory Board. Ross is the founder of GSCG affiliate Kimera Labs in Miami. ... where he studied hematopoietic stem cell transplantation for hematologic disorders and the suppression of ...
(Date:4/26/2016)... ... 26, 2016 , ... BaseHealth , the comprehensive predictive ... as Chief Business Officer. Arianpour, a genomics pioneer and visionary commercial leader with ... recently Chief Commercial Officer of Pathway Genomics. He has held senior executive roles ...
(Date:4/26/2016)... ... 2016 , ... BioFactura, Inc ., a biopharmaceutical research and manufacturing company, ... investor interest drove significant oversubscription of the original $1.5M target. The funds will ... advanced preclinical stages. , Chief Executive Officer and President, Darryl Sampey founded ...
Breaking Biology Technology: